Compare Ionis Pharmaceuticals Inc. Common Stock (IONS) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ionis Pharmaceuticals Inc. Common Stock vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Ionis Pharmaceuticals Inc. Common Stock trades at $43 (market cap $7.04B), while iShares 20 Plus Year Treasury Bond ETF trades at $79.93 (market cap $48.65B). The key difference: iShares 20 Plus Year Treasury Bond ETF is far larger — about 6.9× Ionis Pharmaceuticals Inc. Common Stock's market cap, and iShares 20 Plus Year Treasury Bond ETF is trading nearer its 52-week high, Ionis Pharmaceuticals Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ionis Pharmaceuticals Inc. Common Stock for 0 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| IONS | TLT | |
|---|---|---|
Market Cap | $7.04B | $48.65B |
Volume | 2,977,440 | 29,149,160 |
Sector | Health | Fixed Income |
52-Week High | $86.50 | $92.06 |
52-Week Low | $42.38 | $77.11 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $6.60B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $78.89, up 1.08% on the day but remains in a prolonged downtrend, having fallen 46% over five years. Technical indicators are bearish overall, with moving averages and oscillators signaling selling pressure. The fund continues to face headwinds from rising Treasury yields, which recently hit multi-decade highs, though recent PCE data provided some relief.
The outlook for TLT hinges on the direction of long-term interest rates. While current yields near 5.3% offer attractive income, further rate increases could pressure prices lower. Key risks include persistent inflation and Fed policy uncertainty. Investors should weigh high yield against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ionis Pharmaceuticals Inc. Common Stock
Ionis Pharmaceuticals Inc. is a biopharmaceutical company that develops RNA-targeted medicines using its antisense technology, with marketed treatments in neurology and cardiometabolic disease.
Read more on IONS →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
